Column Group III GP’s Insider Sell‑Off Signals New Strategy for Tenaya

Insider Selling by Column Group III GP, LP Signals a Shift in Ownership Dynamics

The most recent Form 4 filing on February 10 2026 documents a significant divestiture by Column Group III GP, LP (TCG III LP), which sold 161,422 shares of Tenaya Therapeutics common stock at an average price of $0.82. A subsequent transaction on the same day added another 182,295 shares sold at the identical price. Two days later, on February 11, TCG III LP completed two further sales: 1,905,115 shares and 2,151,458 shares, each at $0.68. After these trades the partnership’s holding was reduced to 2,651,817 shares, representing roughly 4 % of the outstanding shares. The pattern indicates a systematic, tranche‑based divestment rather than a one‑off liquidation.

Impact on Market Perception and Liquidity

The timing of the sales is noteworthy. They occurred amid a sharp decline in Tenaya’s share price—an 8.8 % drop over the week and 9.9 % over the month. Although the trades do not trigger a wash sale or insider‑trading violation, the volume of shares being off‑loaded could strain liquidity and exert downward pressure on price if market participants interpret the action as a lack of confidence. A sentiment score of +37 and a buzz level of 59 % suggest that the market is reacting positively, implying that investors view these transactions as routine portfolio rebalancing rather than a negative signal. Nonetheless, cumulative insider sales may elevate short‑term volatility and could prompt analysts to reassess Tenaya’s valuation, especially given its negative earnings and a price‑to‑earnings ratio of –1.12.

Column Group III GP, LP: A Strategic Player

Column Group III GP, LP is the general partner of several limited partnerships—including TCG III LP, TCG III‑A LP, and TCG Opportunity III LP. Historically, the group has maintained a sizeable stake in Tenaya, holding nearly 49.3 million shares. The recent sales at $0.82 and $0.68 suggest the partnership is capitalizing on short‑term price movements while retaining a residual position for long‑term exposure. This opportunistic harvesting strategy—selling when the market price appears favorable relative to the cost basis and holding enough shares to benefit from future upside—aligns with a long‑term investment philosophy that balances liquidity needs with potential upside from the company’s therapeutic pipeline.

Market Context and Strategic Outlook

Tenaya’s stock remains highly volatile, with a 52‑week range from $0.36 to $2.35. The company’s focus on heart‑disease therapies places it in a competitive biotech niche, yet negative earnings and a high beta expose investors to significant risk. Insider activity, such as the recent TCG III GP, LP sales, is one of many indicators that can influence market perception. Analysts will likely monitor whether remaining insider holdings continue to decline or stabilize, and whether new insider purchases emerge that could signal confidence in forthcoming clinical milestones. For investors, the key takeaway is that while insider divestments add a layer of uncertainty, the overall impact will depend on Tenaya’s ability to deliver on its therapeutic agenda and to navigate a challenging funding environment.

Transaction Summary